Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study ProtocolBenjamin Levy, Jonathan W. Riess, Luis Paz‐Ares et al.|Clinical Lung Cancer|2019Cited by 10
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)Benjamin Levy, Jonathan W. Riess, Fabrice Barlési et al.|Lung Cancer|2022Cited by 7
658 A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancerPaul Rhee, Michael Chisamore, Byoung Yong Shim et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2
Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475Adam Grant, George E. Katibah, Juraj Adamik et al.|Cancer Research|2024Cited by 1
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.Do‐Youn Oh, Young Su Noh, Min-Hee Ryu et al.|Journal of Clinical Oncology|2025Cited by 0